Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$21.90
-1.04 (-4.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-271.8M · quality 70.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-33.3%
↓Gross Margin
11.5%
↓Debt/Equity
0.23
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-272821.8%
FCF / Net income
1.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $165000.0 · net income $-253.4M · FCF $-450.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $165000.00 | $165000.00 | — | — | — |
| Net Income | $-253.4M | $-253.4M | $-182.2M | $-249.6M | $-289.0M |
| EBITDA | $-249.2M | $-249.2M | $-177.6M | $-242.3M | $-281.0M |
| EPS | -2.44 | -2.44 | -1.76 | -2.67 | -3.09 |
| Gross Margin | 11.5% | 11.5% | — | — | — |
| Operating Margin | -145784.2% | -145784.2% | — | — | — |
| Net Margin | -153589.1% | -153589.1% | — | — | — |
| Balance Sheet | |||||
| Debt/Equity | 0.23 | 0.23 | 0.01 | 0.01 | 0.01 |
| Current Ratio | 4.47 | 4.47 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-450.2M | $-450.2M | $-141.0M | $-271.8M | $-248.3M |
| Returns | |||||
| ROE | -33.3% | -33.3% | -75.5% | -63.8% | -44.3% |
| Valuation | |||||
| P/B | 2.98 | 2.98 | — | — | — |
| Growth & Yield | |||||
| EPS Growth | -38.6% | -38.6% | 34.1% | 13.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-53.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.76 → -2.44
Residual
-53.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.